Soe77
2021-10-28
Ho say liaoz!
Merck raises full-year profit target after cancer drug sales help Q3 beat
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":854326061,"tweetId":"854326061","gmtCreate":1635421667514,"gmtModify":1635421667628,"author":{"id":4092299591527610,"idStr":"4092299591527610","authorId":4092299591527610,"authorIdStr":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ho say liaoz!</p></body></html>","htmlText":"<html><head></head><body><p>Ho say liaoz!</p></body></html>","text":"Ho say liaoz!","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/854326061","repostId":2178265612,"repostType":4,"repost":{"id":"2178265612","pubTimestamp":1635421212,"share":"https://www.laohu8.com/m/news/2178265612?lang=&edition=full","pubTime":"2021-10-28 19:40","market":"us","language":"en","title":"Merck raises full-year profit target after cancer drug sales help Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2178265612","media":"Reuters","summary":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong de","content":"<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.</p>\n<p>Sales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.</p>\n<p>The company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.</p>\n<p>The forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.</p>\n<p>Merck's shares rose 2.4% before the opening bell.</p>\n<p><img src=\"https://static.tigerbbs.com/b7cb17007b56605e17fcfbaa50ab19e1\" tg-width=\"883\" tg-height=\"598\" width=\"100%\" height=\"auto\"></p>\n<p>The company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>Merck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.</p>\n<p>Net income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.</p>\n<p>Excluding <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.</p>\n<p>Sales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.</p>\n<p>Sales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck raises full-year profit target after cancer drug sales help Q3 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck raises full-year profit target after cancer drug sales help Q3 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 19:40 GMT+8 <a href=https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2178265612","content_text":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.\nSales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.\nThe company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.\nThe forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.\nMerck's shares rose 2.4% before the opening bell.\n\nThe company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.\nNet income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.\nExcluding one-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.\nSales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.\nSales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":814,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/854326061"}
精彩评论